BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 33838758)

  • 1. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
    Marson A; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton C; Hughes DA; Williamson P; Baker GA; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE;
    Lancet; 2021 Apr; 397(10282):1375-1386. PubMed ID: 33838758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
    Marson A; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton C; Hughes DA; Williamson P; Baker GA; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE;
    Lancet; 2021 Apr; 397(10282):1363-1374. PubMed ID: 33838757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.
    Marson AG; Al-Kharusi AM; Alwaidh M; Appleton R; Baker GA; Chadwick DW; Cramp C; Cockerell OC; Cooper PN; Doughty J; Eaton B; Gamble C; Goulding PJ; Howell SJ; Hughes A; Jackson M; Jacoby A; Kellett M; Lawson GR; Leach JP; Nicolaides P; Roberts R; Shackley P; Shen J; Smith DF; Smith PE; Smith CT; Vanoli A; Williamson PR;
    Lancet; 2007 Mar; 369(9566):1016-26. PubMed ID: 17382828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II).
    Balabanova S; Taylor C; Sills G; Burnside G; Plumpton C; Smith PEM; Appleton R; Leach JP; Johnson M; Baker G; Pirmohamed M; Hughes DA; Williamson PR; Tudur-Smith C; Marson AG
    BMJ Open; 2020 Aug; 10(8):e040635. PubMed ID: 32847927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the EcLiPSE RCT.
    Appleton RE; Rainford NE; Gamble C; Messahel S; Humphreys A; Hickey H; Woolfall K; Roper L; Noblet J; Lee E; Potter S; Tate P; Al Najjar N; Iyer A; Evans V; Lyttle MD
    Health Technol Assess; 2020 Nov; 24(58):1-96. PubMed ID: 33190679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial.
    Marson AG; Appleton R; Baker GA; Chadwick DW; Doughty J; Eaton B; Gamble C; Jacoby A; Shackley P; Smith DF; Tudur-Smith C; Vanoli A; Williamson PR
    Health Technol Assess; 2007 Oct; 11(37):iii-iv, ix-x, 1-134. PubMed ID: 17903391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review.
    Nevitt SJ; Sudell M; Tudur Smith C; Marson AG
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012065. PubMed ID: 31233229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
    Brown JE; Royle KL; Gregory W; Ralph C; Maraveyas A; Din O; Eisen T; Nathan P; Powles T; Griffiths R; Jones R; Vasudev N; Wheater M; Hamid A; Waddell T; McMenemin R; Patel P; Larkin J; Faust G; Martin A; Swain J; Bestall J; McCabe C; Meads D; Goh V; Min Wah T; Brown J; Hewison J; Selby P; Collinson F;
    Lancet Oncol; 2023 Mar; 24(3):213-227. PubMed ID: 36796394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.
    Chamberlain JM; Kapur J; Shinnar S; Elm J; Holsti M; Babcock L; Rogers A; Barsan W; Cloyd J; Lowenstein D; Bleck TP; Conwit R; Meinzer C; Cock H; Fountain NB; Underwood E; Connor JT; Silbergleit R; ;
    Lancet; 2020 Apr; 395(10231):1217-1224. PubMed ID: 32203691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.
    Nevitt SJ; Marson AG; Weston J; Tudur Smith C
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD001911. PubMed ID: 28240353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.
    Wilby J; Kainth A; Hawkins N; Epstein D; McIntosh H; McDaid C; Mason A; Golder S; O'Meara S; Sculpher M; Drummond M; Forbes C
    Health Technol Assess; 2005 Apr; 9(15):1-157, iii-iv. PubMed ID: 15842952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy.
    Trinka E; Marson AG; Van Paesschen W; Kälviäinen R; Marovac J; Duncan B; Buyle S; Hallström Y; Hon P; Muscas GC; Newton M; Meencke HJ; Smith PE; Pohlmann-Eden B;
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1138-47. PubMed ID: 22933814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.
    Nolan SJ; Marson AG; Weston J; Tudur Smith C
    Cochrane Database Syst Rev; 2015 Aug; (8):CD001911. PubMed ID: 26275105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review.
    Nolan SJ; Marson AG; Weston J; Tudur Smith C
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD001904. PubMed ID: 27976799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review.
    Nolan SJ; Marson AG; Weston J; Tudur Smith C
    Cochrane Database Syst Rev; 2015 Jul; (7):CD001904. PubMed ID: 26204241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Person-centred experiential therapy versus cognitive behavioural therapy delivered in the English Improving Access to Psychological Therapies service for the treatment of moderate or severe depression (PRaCTICED): a pragmatic, randomised, non-inferiority trial.
    Barkham M; Saxon D; Hardy GE; Bradburn M; Galloway D; Wickramasekera N; Keetharuth AD; Bower P; King M; Elliott R; Gabriel L; Kellett S; Shaw S; Wilkinson T; Connell J; Harrison P; Ardern K; Bishop-Edwards L; Ashley K; Ohlsen S; Pilling S; Waller G; Brazier JE
    Lancet Psychiatry; 2021 Jun; 8(6):487-499. PubMed ID: 34000240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.
    Baulac M; Rosenow F; Toledo M; Terada K; Li T; De Backer M; Werhahn KJ; Brock M
    Lancet Neurol; 2017 Jan; 16(1):43-54. PubMed ID: 27889312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial.
    Lyttle MD; Rainford NEA; Gamble C; Messahel S; Humphreys A; Hickey H; Woolfall K; Roper L; Noblet J; Lee ED; Potter S; Tate P; Iyer A; Evans V; Appleton RE;
    Lancet; 2019 May; 393(10186):2125-2134. PubMed ID: 31005385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effectiveness of the psychological therapy Mental Health Intervention for Children with Epilepsy in addition to usual care compared with assessment-enhanced usual care alone: a multicentre, randomised controlled clinical trial in the UK.
    Bennett SD; Cross JH; Chowdhury K; Ford T; Heyman I; Coughtrey AE; Dalrymple E; Byford S; Chorpita B; Fonagy P; Moss-Morris R; Reilly C; Smith JA; Stephenson T; Varadkar S; Blackstone J; Quartly H; Hughes T; Lewins A; Moore E; Walji F; Welch A; Whelan E; Zacharia A; D'Oelsnitz A; Shah M; Xu L; Vezyroglou A; Mitchell K; Nizza IE; Ganguli P; Shafran R
    Lancet; 2024 Mar; 403(10433):1254-1266. PubMed ID: 38461840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.